and treatments has and will continue to depend upon ourthe Company’s customers’ ability to obtain an appropriate level of coverage for, and appropriate reimbursement from third-party payers for, these products and treatments. In the United States, CMSThe Centers for Medicare and Medicaid Services (“CMS”) establishes coverage and reimbursement policies for healthcare providers treating Medicare and Medicaid beneficiaries. Under current CMS policies, varying reimbursement levels have been established for ourthe Company’s products and treatments. In the absence of a national coverage determination, coverage policies for Medicare patients may vary by regional Medicare Administrative Contractors. Reimbursement rates for treatments vary based on the geographic price index, the site of service, and other factors. Coverage and reimbursement policies and rates applicable to patients with private insurance are dependent upon individual private payer decisions which may not follow the policies and rates established by CMS. The use of ourCompany products and treatments outside the United States is similarly affected by coverage and reimbursement policies adopted by foreign governments and, to a lesser extent, private insurance carriers. On September 18,29, 2020, CMS finalized a rule regarding its new RO Model, designed, according to CMS, to improve the quality of care for cancer patients receiving radiotherapy and reduce Medicare expenditures through bundled payments. In the final notice, CMS did not include IORT treatments (including CPT codes 77424, 77425, and 77425)77469) within the new alternative payment model for radiation oncology. As a result, whether or not a particular physician practice or hospital is subject to the new radiation oncology payment model, IORT services covered by Medicare will continue to be subject to the existing payment systems for physician services and hospital outpatient services. On December 2, 2020, CMS announced10, 2021, the interim final rule related to CMS’s newProtecting Medicare and American Farmers from Sequestration Cuts Act delayed the RO Model which will take effectimplementation until no earlier than January 1, 2022. We2023. Management cannot provide assurance that government or private third-party payers will continue to reimburse ourthe Company’s products or services, nor can wemanagement provide assurance that the payment rates will be adequate. If providers and physicians are unable to obtain adequate reimbursement for ourthe Company’s products or services, this could have a material adverse effect on ourthe Company’s business and operations. In addition, in the event that the current methodology for calculating payment for these products or services changes, this could have a material adverse effect on ourthe Company’s business and business operations. We

Furthermore, ourthe Company’s customers might use ourits software together with products from other companies or those that they have developed internally. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when ourthe Company’s software does not cause these problems, the existence of these errors might cause usthe Company to incur significant costs, divert the attention of ourits technical personnel from ourthe Company’s solution development efforts;efforts or impact ourits reputation and cause significant customer relations problems.